Biotech upstarts test new biz models to provide returns

Xconomy's Luke Timmerman has a column today that is provocatively called "How to make money in biotech with no hope of going public, slim odds of getting acquired." Indeed, biotech start-ups have adopted corporate structures that offer investors returns without the firms completing IPOs or being acquired by Big Pharma companies. Timmerman points to Seattle-based Resolve Therapeutics, which was organized as a limited liability company to offer returns to investors if the firm lands a licensing deal with another company. We've also seen this LLC model adopted at Cambridge, MA-based Nimbus Discovery, whose interesting virtual drug discovery strategy I covered for my column in FierceBiotech IT last week. Article

Suggested Articles

Allergan is returning rights to brazikumab but funding the cost of development in Crohn’s disease and ulcerative colitis.

Quench Bio is going after a family of proteins involved in inflammatory cell death to treat inflammatory diseases in a more holistic way.

What a difference a day makes in biotech.